Phase IIA Single-Arm Study of Treatment of Patients With Advanced Liver Cancer With a Combination of TATE (Transarterial Tirapazamine Embolization) Followed by an Anti-PD-1 Monoclonal Antibody

Trial Profile

Phase IIA Single-Arm Study of Treatment of Patients With Advanced Liver Cancer With a Combination of TATE (Transarterial Tirapazamine Embolization) Followed by an Anti-PD-1 Monoclonal Antibody

Recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Aug 2017

At a glance

  • Drugs Tirapazamine (Primary) ; Nivolumab; Pembrolizumab
  • Indications Colorectal cancer; Liver cancer
  • Focus Therapeutic Use
  • Acronyms TATE-PD1
  • Sponsors Teclison
  • Most Recent Events

    • 29 Aug 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top